Cohance Lifesciences Ltd
Cohance Lifesciences Ltd (COHANCE) last traded at ₹447, a market capitalisation of ₹17,096 crore, on a P/E of 159. Over the past 52 weeks the stock has ranged between ₹267 and ₹1,039. Cohance Lifesciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹422 crore and net profit of ₹-45 crore. Cohance Lifesciences Ltd’s annual general meeting is scheduled for 17 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Cohance Lifesciences Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Cohance Lifesciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹422 cr, down 23.1% from ₹549 cr a year earlier. Net profit swung to a loss of ₹45 cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 604 | 676 | 840 | 549 | 556 | 545 | 619 | 422 |
| Expenses | 398 | 439 | 611 | 437 | 435 | 449 | 520 | 421 |
| Operating profit | 205 | 237 | 229 | 112 | 121 | 95 | 99 | 1 |
| OPM % | 34% | 35% | 27% | 20% | 22% | 18% | 16% | 0.3% |
| Other income | 16 | 22 | -4 | 6 | 16 | 1 | -18 | 12 |
| Interest | 10 | 11 | 10 | 10 | 9 | 9 | 9 | 7 |
| Depreciation | 38 | 44 | 54 | 45 | 44 | 47 | 51 | 50 |
| Profit before tax | 174 | 205 | 161 | 63 | 84 | 41 | 20 | -43 |
| Tax % | 21% | 25% | 27% | 26% | 21% | 29% | 58% | 5% |
| Net profit | 138 | 153 | 117 | 46 | 66 | 29 | 8 | -45 |
| EPS (₹) | 5.44 | 6.01 | 4.73 | 1.28 | 1.94 | 0.96 | 0.51 | -0.63 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Cohance Lifesciences Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,010 | 1,320 | 1,340 | 1,051 | 1,198 | 2,269 | 2,142 |
| Operating profit | 443 | 582 | 574 | 406 | 375 | 427 | 316 |
| OPM % | 44% | 44% | 43% | 39% | 31% | 19% | 15% |
| Net profit | 362 | 454 | 411 | 300 | 265 | 150 | 59 |
| EPS (₹) | 14.23 | 17.83 | 16.16 | 11.80 | 10.52 | 4.68 | 2.78 |
TTM is the trailing twelve months to the most recent quarter.
Cohance Lifesciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- 18%
- 3 Years
- 19%
- TTM
- -20%
- 10 Years
- %
- 5 Years
- -11%
- 3 Years
- -21%
- TTM
- -77%
- 10 Years
- %
- 5 Years
- -4%
- 3 Years
- -5%
- 1 Year
- -50%
- 10 Years
- %
- 5 Years
- 16%
- 3 Years
- 11%
- Last Year
- 7%
Cohance Lifesciences Ltd shareholding pattern
Promoters held 57.49% at Jun 2026, down from 66.41% at Jun 2025. FIIs 6.50% and DIIs 20.09%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.10% | 50.10% | 50.10% | 66.41% | 57.49% | 57.49% | 57.49% | 57.49% |
| FIIs | 10.70% | 10.84% | 11.05% | 7.23% | 6.51% | 6.01% | 5.59% | 6.50% |
| DIIs | 16.95% | 16.67% | 16.60% | 11.40% | 20.81% | 21.57% | 21.79% | 20.09% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 22.26% | 22.37% | 22.24% | 14.95% | 15.16% | 14.91% | 15.11% | 15.92% |
| No. of shareholders | 69,337 | 84,210 | 86,325 | 80,910 | 75,284 | 81,877 | 85,230 | 99,149 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Cohance Lifesciences Ltd’s AGM?
Cohance Lifesciences Ltd’s annual general meeting is scheduled for 17 Sept 2026.
- AGM8th Annual General Meeting of the members
See the full results calendar for every Indian company reporting in the next 30 days.
Cohance Lifesciences Ltd corporate filings
- Credit RatingCompany Updatehigh impact
Cruxal's analysis: Cohance Lifesciences Limited has requested the withdrawal of its credit ratings from…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DSP Trustee Pvt LtdInsider Trading / SASTlow impact
Cruxal's analysis: Cohance Lifesciences Limited has seen a reduction in shareholding by DSP Trustee Private…
Read the full analysis - Earnings Call TranscriptCompany Updatehigh impact
Cruxal's analysis: Cohance Lifesciences reported a challenging Q1 FY27 with consolidated revenue of 422.3…
Read the full analysis - Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Cohance Lifesciences has published its financial results in newspapers as per Regulation…
Read the full analysis - Completion of USFDA InspectionCompany Updatemedium impact
Cruxal's analysis: Cohance Lifesciences has formally announced the completion of a USFDA inspection. As a…
Read the full analysis - Outcome of the Board MeetingBoard Meetinghigh impact
Cruxal's analysis: Cohance Lifesciences reported a challenging Q1 FY27 with consolidated revenue of 422.26…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Cohance Lifesciences Ltd
Cruxal reads every Cohance Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.